🇺🇸 FDA
Patent

US 11629195

Anti-IL2 receptor gamma antigen-binding proteins

granted A61KA61K2039/505A61K39/3955

Quick answer

US patent 11629195 (Anti-IL2 receptor gamma antigen-binding proteins) held by REGENERON PHARMACEUTICALS, INC. expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Apr 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K2039/505, A61K39/3955, A61K9/0019, A61P